Pharmaceutical companies provide one of the, if not the, most important products to HCPs - the medical advances that make a huge difference to patient outcomes. But bringing new me
The need for pharmaceutical companies to meet or, ideally exceed, the expectations their customers have of them is not new to the industry. Yet new research indicates that many in
Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need
Overview
Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
